or Try an Advanced Search...

    Adverum Biotechnologies Stocks List

    Symbol Grade Name % Change
    ADVM F Adverum Biotechnologies, Inc. 5.04
    CLSD F Clearside Biomedical, Inc. 5.88
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Macular Degeneration Retina Wet Age Related Macular Degeneration Biopharmaceutical Disease Drug Therapies Eye Gene Therapy Gene Therapy Of The Human Retina Gene Therapy Products Genetic Diseases Macular Edema Medicine Non Infectious Uveitis Ophthalmology Rare Genetic Disease Regeneron Retinal Vein Occlusion Uveitis Veins

    Related ETFs - A few ETFs which own one or more of the above listed Adverum Biotechnologies stocks.

    Symbol Grade Name Weight
    EVNT C AltShares Event-Driven ETF 0.33
    IWC B iShares Microcap ETF 0.05
    IWN B iShares Russell 2000 Value ETF 0.01
    IWM B iShares Russell 2000 ETF 0.0
    VXF A Vanguard Extended Market ETF 0.0
    View all Adverum Biotechnologies ETFs...
    Compare ETFs
    Compare EVNT to IWC Compare EVNT to IWN Compare IWC to IWM

        Adverum Biotechnologies Stocks Recent News

        Date Stock Title
        Nov 20 ADVM Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
        Nov 18 ADVM Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
        Nov 18 ADVM Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell
        Nov 18 ADVM Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
        Related Industries: Biotechnology
        Related Stock Lists: Macular Degeneration Retina Wet Age Related Macular Degeneration Biopharmaceutical Disease Drug Therapies Eye Gene Therapy Gene Therapy Of The Human Retina Gene Therapy Products Genetic Diseases Macular Edema Medicine Non Infectious Uveitis Ophthalmology Rare Genetic Disease Regeneron Retinal Vein Occlusion Uveitis Veins
        Adverum Biotechnologies

        Avalanche Biotechnologies is a publicly traded (NASDAQ:AAVL) biotechnology company in the NASDAQ Biotechnology Index that is focused on diseases of the eye. This includes macular degeneration, retinal vein occlusion, diabetic macular edema, and others. The company's only drug in clinical trials, AVA-101, designed to treat macular degeneration, had poor results after initial clinical trials in 2015. In 2016 Avalanche Biotechnologies merged with Annapurna Therapeutics to form Advertum Biotechnologies, Inc.

        More about Adverum Biotechnologies
        Browse All Tags